EarningsQ4 2023 Earnings Report

Kodiak Sciences (KOD) Q4 2023 Earnings Report

0 Followers

Previous Report: Q3 2023

Next Report: Q1 2024

MX:KOD Q4 2023 EPS Results

Actual EPS-$20.54

Consensus EPS-$14.07

Beat/MissMissed by -$6.47

One Year Ago EPS-$24.54

MX:KOD Q4 2023 Revenue Results

Actual Revenue$0.00

Expected Revenue$0.00

Beat/MissMet expectations

YoY Revenue Growth―

Earnings Announcement Details

QuarterQ4 2023

Date03/28/2024

TimeBefore Open

Conference CallThursday, March 28, 2024

MX:KOD Upcoming Earnings

Kodiak Sciences's next earnings date is estimated for November 12, 2026, based on past reporting schedules.

Q4 2023 Earnings Call Audio

MX:KOD Q4 2023 Earnings Call

0:00 / 0:00

Q4 2023 Earnings Slide Deck

Q4 2023 Earnings Call Summary

Q4 2023

Earnings Call Date:Mar 28, 2024|

% Change Since:

Earnings Call Sentiment|Positive

The earnings call highlighted Kodiak Sciences' strong pipeline and positive Phase III outcomes, along with a good financial position. However, there are uncertainties regarding the DAYBREAK study and potential risks if the study does not succeed. Overall, the sentiment leans positive due to the outweighing highlights.

Company Guidance

During the Q4 2023 earnings call for Kodiak Sciences (symbol: KOD) held on March 28, 2024, extensive guidance was provided on the company's strategic direction and clinical program updates. The call highlighted Kodiak's focus on advancing three clinical programs, including two derived from the ABC Platform and one platform-independent. Key metrics discussed included the company's strong cash position as of Q4, the completion of three positive Phase III studies for tarcocimab in diabetic retinopathy, retinal vein occlusion, and wet AMD, and the regulatory alignment achieved for a bridging strategy to the go-to-market formulation. Furthermore, the company outlined plans for additional studies, such as the actively recruiting GLOW2 study in diabetic retinopathy and the inclusion of tarcocimab in the DAYBREAK study to validate its durability in wet AMD. Kodiak aims to progress rapidly into pivotal studies for KSI-501 and KSI-101, with a goal to have four pivotal studies ongoing later in the year. The comprehensive discussion underscored Kodiak's commitment to achieving significant value inflection points within its cash runway extending into 2026.

Strong Pipeline and Diversification

Kodiak Sciences has a portfolio of three clinical programs, two of which are derived from the ABC Platform with focus on durability, and one is platform-independent. This diversification offers both opportunity and risk mitigation.

Positive Phase III Outcomes

Three positive Phase III studies completed for tarcocimab in diabetic retinopathy, retinal vein occlusion, and wet AMD. These studies have shown favorable safety and a strong six-month durability signal.

Regulatory Alignment Achieved

The FDA has agreed on a bridging strategy for the go-to-market formulation of tarcocimab, which is a significant regulatory milestone.

Cash Position

Kodiak is in an attractive cash position as of Q4, providing a runway into 2026 to support their clinical programs and planned pivotal studies.

MX:KOD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 12, 2026	2026 (Q3)	-19.31 / -	-21.087	―
Aug 13, 2026	2026 (Q2)	-17.38 / -19.09	-18.724	-1.94% (-0.36)
May 07, 2026	2026 (Q1)	- / -	-19.814	―
Mar 31, 2026	2025 (Q4)	-17.38 / -17.09	-19.814	13.76% (+2.73)
Nov 13, 2025	2025 (Q3)	-18.85 / -21.09	-15.27	-38.10% (-5.82)
Aug 13, 2025	2025 (Q2)	-19.41 / -18.72	-15.633	-19.77% (-3.09)
May 14, 2025	2025 (Q1)	-16.25 / -19.81	-14.906	-32.93% (-4.91)
Mar 27, 2025	2024 (Q4)	-16.05 / -15.27	-20.541	25.66% (+5.27)
Nov 14, 2024	2024 (Q3)	-16.45 / -15.27	-17.269	11.58% (+2.00)
Aug 14, 2024	2024 (Q2)	-15.85 / -15.63	-27.813	43.79% (+12.18)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed